ABSTRACT
The objectives were to determine the reference intervals of spot urine copper excretion indexes in pre-school children and to evaluate their utility in screening for Wilson disease (WD). With spot urine collected from a control sample of preschool children (aged 3-7 years, n=153), the reference intervals of spot urine copper excretion indexes and their biological variation were defined. In order to investigate their utility performance in screening for WD in this age group, multiple spot urine samples from six WD patients who were diagnosed at presymptomatic stage were also analysed and compared. Cut-off values useful for detection of WD were defined by receiver operator curve (ROC) analysis. Biological (inter-individual) variation of spot urine copper indexes expressed as coefficient of variation (CVg) were around 60% at this age group, which was moderate and similar to other clinically useful urine tests, such as urine albumin excretion ratio. Spot urine copper excretion strongly correlated with both urine creatinine and osmolality. Linear regression against both creatinine and osmolality showed that â¼94% of data points in healthy preschool children fell within the prediction interval, suggesting that both were useful normalisation factors. ROC showed that copper to osmolality ratio was the best index with an area under curve (AUC) greater than 0.98. Cut-off values of 0.5 µmol/L, 0.1 µmol/mmol and 0.00085 µmol/mOsmol (32 µg/L, 56 µg/g creatinine and 0.054 µg/mOsmol, respectively, in conventional units) for spot urine copper concentration, copper to creatinine ratio and copper to osmolality ratio, respectively, have potential application in the differentiation of WD patients. Based on the data, a new WD screening strategy targeting preschool children is proposed. Application of a bivariate screening strategy using spot urine copper concentration and urine osmolality may be useful in a population-wide screening program for WD among preschool children.
Subject(s)
Copper/urine , Hepatolenticular Degeneration/diagnosis , Hepatolenticular Degeneration/urine , Urinalysis/standards , Biological Variation, Individual , Child , Child, Preschool , Creatinine/urine , Female , Humans , Male , Mass Screening/standards , Reference ValuesABSTRACT
OBJECTIVE: A randomized-controlled trial comparing study of the changes in brain sensitive-weighted imaging (SWI) of Wilson disease (WD) patients during the treatment with metal chelator was done. METHODS: 100 untreated WD patients (80 cases of cerebral type, 20 cases of hepatic type, age 20.13 ± 9.12 years old) and 20 normal controls were selected. Neurological symptoms were scored using the modified Young scale. Liver function tests and copper indices were collected. All study objects received SWI test of the brain. The values of corrected phase (CP) were calculated on SWI. Cerebral-type WD patients were treated with D-penicillamine (DPA) (group 1) or Dimercaptopropane Sulfonate (DMPS) + Dimercaptosuccinic Acid (DMSA) (group 2). Hepatic-type WD patients were treated with DPA (group 3). All patients received annual neurological symptom score, liver function, copper indices, and SWI examination. RESULTS: At the first year of treatment, score of the modified Young scale in group 2 was lower than that in group 1 (P = 0.023) and lower than that before treatment (P = 0.040). After 2 years of treatment, the score of the modified Young scale in group 1 was lower than that before treatment (P = 0.012). At the second year after treatment, the urinary copper in group 2 was higher than that in group 1 (P = 0.014). Urinary copper was maintained at 200 µg/day in group 1 and 300 µg/day in group 2 after 3 years of treatment. At the first year of treatment, serum copper in group 1 was lower than that in group 2 (P = 0.032). At the first year of treatment, CP values of the pallidum and substantia nigra in group 2 were higher than those in group 1 (P = 0.026, 0.040). At the second year of treatment, CP value of substantia nigra in group 2 was higher than that in group 1 (P = 0.037). After 3 years of treatment, there was no difference in CP values between WD patients and normal controls. CONCLUSIONS: Therapy with DMPS and DMSA improves neurological symptoms of WD patients more quickly and leads to less aggravation, compared with therapy with DPA. The metal content in the brain of WD patients was at a low level after 3 years of treatment. DMPS and DMSA can remove metal from brain tissue faster than DPA.
Subject(s)
Chelating Agents/pharmacology , Globus Pallidus/diagnostic imaging , Hepatolenticular Degeneration/diagnostic imaging , Hepatolenticular Degeneration/drug therapy , Penicillamine/pharmacology , Substantia Nigra/diagnostic imaging , Unithiol/pharmacology , Adolescent , Adult , Copper/blood , Copper/urine , Female , Hepatolenticular Degeneration/blood , Hepatolenticular Degeneration/urine , Humans , Magnetic Resonance Imaging , Male , Outcome Assessment, Health Care , Young AdultABSTRACT
Background. Available treatments for Wilson disease (WD) prevent longterm complications of copper accumulation. Current anti-copper agents include zinc salts, penicillamine, and trientine. Patients with WD may switch between the agents for a number of reasons. Due to the different mechanisms of action between the copper chelators and zinc salts, transitioning could require a period of overlap and increased monitoring. There are no large studies that investigate the best transition strategies between agents. In this article, we review the treatments for WD and how to monitor for treatment efficacy. Case Summary. The patient had been diagnosed with WD for over 20 years prior to establishing care in our Hepatology Clinic. During his initial course, he was transitioned from penicillamine to zinc due to evidence suggesting penicillamine had greater adverse effects in the long term. Later, he was switched to trientine. His liver enzymes and 24-hour urine copper were monitored. During these years, he intermittently had some financial hardship, requiring him to be on penicillamine rather than trientine. He also had developed acute kidney injury. Overall, his liver disease remained under control and he never had signs of decompensated cirrhosis, but had fluctuations of liver enzymes over the years. Conclusion. Anti-copper treatment for WD has to be tailored to medication side effects profile, patient's chronic and emerging comorbidities, as well as costs. Transitioning regimens is often challenging, and it requires closer monitoring, with no predictors of response.
Subject(s)
Acute Kidney Injury/chemically induced , Chelating Agents/adverse effects , Copper/urine , Hepatolenticular Degeneration/drug therapy , Adult , Chelating Agents/economics , Hepatolenticular Degeneration/urine , Humans , Liver/physiopathology , Male , Penicillamine/adverse effects , Treatment Outcome , Trientine/adverse effects , Zinc/therapeutic useABSTRACT
OBJECTIVE: Urinary copper excretion rates and non-caeruloplasmin associated copper concentrations are increased in patients with Wilson disease. However, there is little literature describing the monitoring of these parameters over the long term. METHODS: This is a monocentric retrospective study including data collected between 2003 and 2015 from 321 patients with Wilson disease by chart review. The patients were under therapy with D-penicillamine, trientine, or zinc. 24-h urinary copper excretion rates, non-caeruloplasmin associated copper, and total serum copper concentrations were determined at the start of therapy, as well as 6, 12, 18, 24, 36, and ≥ 60 months after the start of therapy. For patients taking chelating agents, all parameters were measured while under continued therapy, as well as after a 48-h dose interruption. A mathematical formula to predict 24-h urinary copper excretion rates under different therapies was established. RESULTS: In all treatment groups, urinary copper excretion rates decreased over time, but the inter-individual variation of the results was high. Non-caeruloplasmin associated copper concentrations tended to decline over time, but with a higher variation of results than that observed for urinary copper excretion rates. CONCLUSION: Due to their variability, urinary copper excretion rates and serum copper concentrations are less than ideal parameters by which to monitor the benefit of a copper-reducing therapy. Urinary copper excretion rates seem to be more suitable than non-caeruloplasmin associated copper concentrations for this purpose.
Subject(s)
Copper/urine , Hepatolenticular Degeneration/drug therapy , Penicillamine/therapeutic use , Trientine/therapeutic use , Zinc/therapeutic use , Adolescent , Adult , Ceruloplasmin/metabolism , Chelating Agents/therapeutic use , Child , Child, Preschool , Copper/blood , Copper/metabolism , Female , Germany , Hepatolenticular Degeneration/blood , Hepatolenticular Degeneration/urine , Humans , Infant , Male , Middle Aged , Regression Analysis , Retrospective Studies , Young AdultABSTRACT
Twenty-four-hour (h) urinary copper content is considered as the most suitable tool for the diagnosis of Wilson's disease (WD); however, it is less accurate, time-consuming, and non-economical. Consequently, in the present study, an alternative method through measuring the morning (first) urine copper (Cu) concentration is proposed for the diagnosis of WD, which is more accurate, precise, faster, and cheaper. For this purpose, a sensitive, accurate, and precise analytical method was developed and validated in regard to Commission Decision 657/2002/EC, Council Directive 333/2007/EC, ISO/IEC 17025:2005, and EURACHEM 1998 for the determination of Cu in urine using flame atomic absorption spectrometry (FAAS). The methods LoD and LoQ for urine Cu were estimated as 6.68 µg/L and 16.7 µg/L respectively. The accuracy of the method was found to be 93.70-101.88% calculated from the spike recovery experiment. The RSDs for the repeatability and reproducibility precision were measured as 0.67-3.16 and 0.26-1.95 respectively. The method validation performance criteria indicated that the method was suitable for the determination of Cu in urine. The validated method was then applied for the determination of Cu in both 24 h and first urine. From the analysis, it was found that the amount of Cu per liter in the first urine was almost equivalent to the amount of Cu per 24 h indicating that instead of considering the 24-h urine, morning (first) urine investigation might be an alternative approach for the diagnosis of WD.
Subject(s)
Copper/urine , Hepatolenticular Degeneration/diagnosis , Hepatolenticular Degeneration/urine , Humans , Quality Control , Spectrophotometry, AtomicABSTRACT
The optimal cut-off value of 24-hour (h) urinary copper (Cu) levels to identify Wilson's disease (WD) has not been widely studied in children. In sixty-six children with confirmed WD and 88 children without WD, 24-h urinary excretion of Cu at the time of diagnosis was studied. The receiver operating characteristic (ROC) curves revealed that the optimal cut-off value of urinary Cu to identify WD was 70 mcg [area under the curve (AUC) = 0.894] with a sensitivity and specificity of 81.8% and 89.8%, respectively. When the serum ceruloplasmin level was < 20 mg/dl and the 24-h urinary excretion of Cu was >70 mcg, the sensitivity was 75.8%, and the specificity was 97.7%. After the exclusion of cholestatic patients, the ROC curves revealed that the optimal cut-off value for 24-h urinary Cu excretion was 55 mcg (AUC = 0.910) with a sensitivity and specificity of 83.3% and 90.3%, respectively. When the ceruloplasmin level was <20 mg/dl and the 24-h urinary Cu excretion was >55 mcg, the sensitivity and specificity were 77.3% and 98.4%, respectively. A 24-h urinary Cu level of >70 mcg plus a ceruloplasmin level of < 20 mg/dl in the patients, and a 24-h urinary Cu level of >55 mcg plus a ceruloplasmin level of <20 mg/dl in non-cholestatic patients exhibited the highest specificity and the highest positive and negative predictive values to identify WD in children.
Subject(s)
Copper/urine , Hepatolenticular Degeneration/diagnosis , Adolescent , Case-Control Studies , Ceruloplasmin/metabolism , Child , Female , Hepatolenticular Degeneration/metabolism , Hepatolenticular Degeneration/urine , Humans , Male , ROC Curve , Sensitivity and SpecificityABSTRACT
The performance characteristics of a new selective and sensitive modified screen printed electrode (MSPE; electrode I) and carbon paste electrode (MCPE; electrode II) based on 2-N, N-dimethylcarbamimidoyl (metformin) as modifier for the potentiometric determination of copper (II) in water sample, serum and urine samples of Wilson disease patients have been optimized. The chemical reaction which happens between Cu (II) and the modifier on the surface of the sensors was investigated with scanning electron microscope (SEM), energy dispersive X-ray analysis (EDX), IR spectra measurement and computational calculations at DFT/B3LYP. The sensors showed perfect potentiometric response for Cu (II) over concentration range of 1.0â¯×â¯10-6 - 1.0â¯×â¯10-2 and 1.0â¯×â¯10-6 - 5.0â¯×â¯10-2 molâ¯L-1 with a detection limit of 1.0â¯×â¯10-6 molâ¯L-1with divalent slope value 30.2 and 31.8â¯mV decade-1 over the pH range of 2-6 for MCPE and MSPE, respectively. MSPE was stable with repeatable potential over period of 37 days and exhibits fast response time of 6 and 10â¯s for MSPE and MCPE, respectively. Also, these sensors exhibited good selectivity towards Cu(II) with respect to other metal ions and have higher antibacterial activity against Staphylococcus aureus as Gram-positive bacteria and Escherichia coli as Gram-negative bacteria. The obtained results using the sensors were in agreement with those obtained using the reported method.
Subject(s)
Biosensing Techniques/instrumentation , Biosensing Techniques/methods , Carbon/chemistry , Copper/analysis , Copper/chemistry , Hepatolenticular Degeneration/diagnosis , Blood Chemical Analysis/instrumentation , Copper/blood , Copper/urine , Electrodes , Hepatolenticular Degeneration/blood , Hepatolenticular Degeneration/urine , Humans , Hydrogen-Ion Concentration , Urinalysis/instrumentation , Water/chemistryABSTRACT
BACKGROUND: Experience with zinc in treating symptomatic hepatic Wilson's disease (WD) is limited. AIM: To study the efficacy of Penicillamine followed by zinc in treating symptomatic hepatic Wilson's disease. METHODS: We retrospectively analyzed case records of 31 symptomatic hepatic WD patients for whom disease severity scores (Child's, model for end-stage liver disease (MELD), Nazer's, and New Wilson Index (NWI) score) and 24-h urinary copper were compared at 3-time points-baseline at presentation, at transition from penicillamine to zinc and at end of follow up. RESULTS: Thirty-one patients (median age 11 [5-24] years) with symptomatic hepatic WD were studied; ten had associated neuropsychiatric manifestations of WD. Penicillamine was changed to zinc sulfate either due to financial constraints (28 patients) or due to adverse effects of penicillamine (3 patients). At presentation (baseline), six patients belonged to Child's class A, five to Child's B, and 17 to Child's C. Duration of initial penicillamine chelation therapy was 134 (2-320) weeks, and of subsequent zinc therapy was 363 (35-728) weeks. There was a significant improvement in liver function tests and disease severity scores (Child's, MELD, Nazer's, and NWI score) at the transition from penicillamine to zinc compared to baseline. This improvement was maintained until the end of study period with 90% survival at 10 (2-20) years. Fifteen of the 17 Child's C cirrhotic patients showed significant improvement in disease severity scores from baseline until end of follow up. CONCLUSIONS: Penicillamine followed by zinc may be a safe and effective treatment in resource-constrained setting for symptomatic hepatic WD patients in all grades of baseline disease severity. Some patients with decompensated cirrhosis due to WD may be managed with medical treatment, avoiding liver transplantation.
Subject(s)
Chelating Agents/administration & dosage , Chelating Agents/economics , Cost Savings , Drug Substitution , Hepatolenticular Degeneration/drug therapy , Penicillamine/administration & dosage , Penicillamine/economics , Zinc Sulfate/administration & dosage , Zinc Sulfate/economics , Adolescent , Adult , Child , Child, Preschool , Copper/urine , Female , Follow-Up Studies , Hepatolenticular Degeneration/urine , Humans , Male , Retrospective Studies , Severity of Illness Index , Time Factors , Treatment Outcome , Young AdultABSTRACT
Abnormal handling of copper is the cause of Wilson disease (WD), a rare disorder typified by increased levels in plasma copper not-bound to ceruloplasmin (nCp-Cu, also known as 'free' copper). In Alzheimer's disease (AD), meta-analyses show that copper decreases in brain but increases in serum, due to the nCp Cu component increase. Despite the similarities, a direct comparison of copper biological status in the two diseases has never been carried out. To fill this gap, we evaluated serum copper, ceruloplasmin, nCp-Cu and Cu:Cp in 385 CE and 336 healthy controls previously investigated that were compared with 9 newly diagnosed WD patients. We then assessed 24h copper urinary excretion in 24 WD patients under D-penicillamine (D-pen) treatment and in 35 healthy controls, and compared results with those of AD patients participating to a D-pen phase II clinical trial previously published. After adjusting for sex and age, serum nCp-Cu and Cu:Cp resulted higher in AD and in WD than in healthy controls (both p<0.001). While nCp-Cu was similar between AD and WD, Cu:Cp was higher in WD (p<0.016). 24h urinary copper excretion in AD patients (12.05µg/day) was higher than in healthy controls (4.82µg/day; p<0.001). 77.8% of the AD patients under D-pen treatment had a 24h urinary excretion higher than 200µg/day, suggestive of a failure of copper control. This study provides new insight into the pathophysiology of copper homeostasis in AD, showing a failure of copper control and the Cu:Cp ratio as an eligible marker.
Subject(s)
Alzheimer Disease/blood , Alzheimer Disease/urine , Copper/blood , Copper/urine , Hepatolenticular Degeneration/blood , Hepatolenticular Degeneration/urine , Ceruloplasmin , Female , Humans , MaleABSTRACT
Copper is an essential nutrient for life, but at the same time, hyperaccumulation of this redox-active metal in biological fluids and tissues is a hallmark of pathologies such as Wilson's and Menkes diseases, various neurodegenerative diseases, and toxic environmental exposure. Diseases characterized by copper hyperaccumulation are currently challenging to identify due to costly diagnostic tools that involve extensive technical workup. Motivated to create simple yet highly selective and sensitive diagnostic tools, we have initiated a program to develop new materials that can enable monitoring of copper levels in biological fluid samples without complex and expensive instrumentation. Herein, we report the design, synthesis, and properties of PAF-1-SMe, a robust three-dimensional porous aromatic framework (PAF) densely functionalized with thioether groups for selective capture and concentration of copper from biofluids as well as aqueous samples. PAF-1-SMe exhibits a high selectivity for copper over other biologically relevant metals, with a saturation capacity reaching over 600 mg/g. Moreover, the combination of PAF-1-SMe as a material for capture and concentration of copper from biological samples with 8-hydroxyquinoline as a colorimetric indicator affords a method for identifying aberrant elevations of copper in urine samples from mice with Wilson's disease and also tracing exogenously added copper in serum. This divide-and-conquer sensing strategy, where functional and robust porous materials serve as molecular recognition elements that can be used to capture and concentrate analytes in conjunction with molecular indicators for signal readouts, establishes a valuable starting point for the use of porous polymeric materials in noninvasive diagnostic applications.
Subject(s)
Copper/urine , Hepatolenticular Degeneration/diagnosis , Polymers , Sulfides , Animals , Disease Models, Animal , Hepatolenticular Degeneration/urine , Mice , Molecular Structure , Polymers/chemical synthesis , Polymers/chemistry , Porosity , Sensitivity and Specificity , Sulfides/chemical synthesis , Sulfides/chemistryABSTRACT
La enfermedad de Wilson es un desorden autosómico recesivo del metabolismo del cobre.Se reporta un caso de cirrosis hepática y anemia hemolítica por enfermedad de Wilson en una adolescente de 13 años de edad. Debuta con cuadro sugestivo de infección urinaria, leucocituria, hematuria, acompañada de íctero de piel y mucosas, hepatomegalia ligera, vómitos y toma del estado general por lo que requiere cuidados intensivos pediátricos durante 5 días. Se le realizaron análisis complementarios compatibles con anemia hemolítica severa, Hb. 53 g/L Hto. 0,17 l/L, reticulocitosis de 180 x103, prueba de Coombs negativa, alteraciones del coagulograma y ligera elevación de las aminotransferasas. El estudio hepático mostró cifras de ceruloplasmina en 0,07 g/L, cobre en orina basal 9,13 µmol/día, cobre el tejido hepático 9,54 µg/g de tejido seco, presencia de anillo de Kayser Fleischer en lámpara de hendidura, laparoscopia con aspecto de una cirrosis hepática micronodular y biopsia hepática con una cirrosis micronodular secundaria a una enfermedad de Wilson.El diagnostico de enfermedad de Wilson deberá tenerse presente en todos aquellos niños que presenten una enfermedad hepática crónica o de evolución tórpida cuya etiología no aparezca clara, de tal manera de evitar el compromiso neurológico que habitualmente es más tardío(AU)
Wilson Disease (WD) is a recessive autosomal disorder in copper metabolism. A hepatic cirrhosis and hemolytic anemia is reported due to WD, in an female adolescent of age 13, with family antecedent of a sister with WD. She debuts presenting what seems to be a urinary infection, leukocyturia, hematuria, together with skin and mucosas icterus, mild hepatomegaly, vomits and generalized state of disease, reason why she requires pediatric intensive care for five days. Complementary analysis were carried out, compatibles with severe hemolytic anemia, HB. 53 g/L, Hto. 0.17i/L, reticulocytosis of 180X103, negative Coombs test, coagulogram alterations, and mild elevation of aminotransferases. The hepatic study show ciphers of ceruloplasmin in 0.07 g/L, copper in basal urine 9.13 µmol per day, copper in hepatic tissue 9,54 µg/g in dry tissue, Kayser Fleischer Ring in slit lamp, laparoscopy with aspect of a micronodular hepatic cirrhosis and liver biopsy with a secondary micronodular cirrhosis to a WD. The WD diagnosis should be taken into account in all children with a crhonic liver disease or torpid evoluction whose etiology is not clear, so that the normally later neurologic compromise may be avoided
Subject(s)
Humans , Adolescent , Hepatolenticular Degeneration/complications , Hepatolenticular Degeneration/metabolism , Hepatolenticular Degeneration/urine , Anemia, Hemolytic/complicationsABSTRACT
Wilson disease is an infrequent autosomal recessive disorder caused by mutations in the ATP7B gene (13q14.3) producing pathologic phenotypes due to copper accumulation in critical tissues. The aim of the research was to probe Wilson disease genetic epidemiology in Venezuela, through the identification in diagnosed index cases, of ATP7B locus mutations, their geographic distribution, frequency, in-phase haplotypes and probable ethnic ancestry. During the last three decades 33 independent Wilson disease families from the country at large were ascertained and diagnosed through severely reduced ceruloplasmin activity, higher urinary copper excretion, and specific clinical signs. Molecular studies of the ATP7B gene were accomplished in 26 of the families. Disease prevalence was estimated as 1:94,000 families between 1985 and 2013, showing geographic aggregation in the state of Zulia with 1:27,000 families in it. DNA analysis in 26 families revealed 13 different mutations. The c.3402delC was the most frequent one (26.9%), presenting two independent in-phase haplotypes, both of likely European descent; which is followed by the not previously reported p.G691V (9.6%) and by the frequent European H1069Q (7.7%). Known mutations c.51 + 4A > T, c.1285 + 5G > T, M645R, T788I, V845SfsX28, T977M, L1088X, T1220M, R1319X and a novel P767L showed frequencies between 5.8 and 1.9%. Despite the ample mutation heterogeneity for Wilson disease in the country, the findings provide a diagnostic algorithm to ease mutation assessment in new patients; the predominant c.3402delC displayed wide geographic distribution and two genetic origins.
Subject(s)
Adenosine Triphosphatases/genetics , Cation Transport Proteins/genetics , Hepatolenticular Degeneration/genetics , Adolescent , Adult , Child , Copper/urine , Copper-Transporting ATPases , Female , Gene Frequency , Hepatolenticular Degeneration/epidemiology , Hepatolenticular Degeneration/urine , Humans , Male , Mutation , Polymorphism, Single Nucleotide , Prevalence , Venezuela/epidemiology , Young AdultABSTRACT
TITLE: Variante del signo de la cara del panda gigante.
Subject(s)
Basal Ganglia/pathology , Hepatolenticular Degeneration/diagnosis , Magnetic Resonance Imaging , Mesencephalon/pathology , Neuroimaging/methods , Adult , Basal Ganglia/chemistry , Brain Chemistry , Copper/analysis , Copper/urine , Hepatolenticular Degeneration/pathology , Hepatolenticular Degeneration/urine , Humans , Iron/analysis , Male , Mesencephalon/chemistryABSTRACT
BACKGROUND: The goal of this study was to determine bone mineralization in children with Wilson's disease (WD). METHODS: Twenty-seven patients (16 males) and two age- and gender-matched healthy children for each patient were enrolled in the study. Bone mineral content (BMC, grams) and density (BMD, g/cm(2)) at lumbar 1-4 vertebrae were measured by dual-energy X-ray absorptiometry. Urinary calcium excretion was calculated in 19 patients. The effect of cirrhosis and hypercalciuria on BMC and BMD was also evaluated in WD patients. RESULTS: There was no statistically significant difference between patients and healthy controls regarding mean BMC (33.0 ± 13.9 vs. 35.8 ± 13.8 g) (p = 0.940) and mean BMD values (0.66 ± 0.16 vs. 0.71 ± 0.18 g/cm(2)) (p = 0.269), respectively. Nine (47.4 %) patients had hypercalciuria. Hypercalciuric patients had statistically significant lower BMC and BMD values than those without hypercalciuria. A significant difference continued to be present after age, weight, height, and pubertal stage adjustment was done, but disappeared after weight, height, follow up duration, and pubertal stage adjustment was done. The presence of cirrhosis did not affect BMC and BMD significantly in WD patients. CONCLUSIONS: BMC and BMD in children with WD were normal. The presence of hypercalciuria but not cirrhosis may affect BMC and BMD negatively in the patients.
Subject(s)
Bone Density , Calcification, Physiologic , Hepatolenticular Degeneration/metabolism , Absorptiometry, Photon , Adolescent , Biomarkers/metabolism , Calcium/administration & dosage , Calcium/urine , Child , Child, Preschool , Cross-Sectional Studies , Female , Hepatolenticular Degeneration/diagnosis , Hepatolenticular Degeneration/therapy , Hepatolenticular Degeneration/urine , Humans , Hypercalciuria , Liver Cirrhosis/metabolism , Lumbar Vertebrae/metabolism , Male , Zinc/administration & dosageABSTRACT
BACKGROUND/AIMS: The differential diagnosis of Wilson Disease (WD) is challenging, especially in children, because liver copper levels may also increase in other chronic liver diseases with bile stasis. The aim of this study is to determine urine and liver copper cut-off values to differentiate WD from other chronic liver diseases (non-WD, NWD) in children. MATERIALS AND METHODS: Seventy-six patients participated in the study, 35 with WD and 41 with NWD. The two groups were divided into two subgroups according to the presence of cholestasis. At the time of diagnosis, age, sex, biochemical test results, serum ceruloplasmin, baseline 24-h urinary copper levels, liver biopsy histological findings, liver copper levels, and Child-Pugh scores were obtained from medical records. Copper content in liver tissue and copper levels in urine were measured by atomic absorption spectrometry. Cut-off values for differentiation of WD from NWD were determined by receiver operating characteristic (ROC) analysis. RESULTS: A liver copper cut-off value of 98 µg/g indicated WD with 91% sensitivity and 65.4% specificity (area under the curve =0.838, 95% CI: 0.749-0.927). A 24-h urinary copper cut-off value of 67.5 µg/24h indicated WD with 85% sensitivity and 71% specificity (area under the curve =0.843, 95% CI: 0.752-0.934). CONCLUSION: In this study of pediatric chronic liver disease patients, copper cut-off values for distinguishing WD differed substantially from those used for diagnosis. A larger scale study is warranted to re-evaluate liver copper and 24-h urinary copper cut-offs for children with suspected WD.
Subject(s)
Copper/analysis , Hepatolenticular Degeneration/diagnosis , Hepatolenticular Degeneration/urine , Liver/chemistry , Adolescent , Child , Chronic Disease , Copper/urine , Diagnosis, Differential , Diagnostic Tests, Routine/standards , Female , Humans , Liver Diseases/diagnosis , Liver Diseases/urine , Male , Retrospective StudiesABSTRACT
Body copper homeostasis is regulated by the liver, which removes excess copper via bile. In Wilson's disease (WD), this function is disrupted due to inactivation of the copper transporter ATP7B resulting in hepatic copper overload. High urinary copper is a diagnostic feature of WD linked to liver malfunction; the mechanism behind urinary copper elevation is not fully understood. Using Positron Emission Tomography-Computed Tomography (PET-CT) imaging of live Atp7b(-/-) mice at different stages of disease, a longitudinal metal analysis, and characterization of copper-binding molecules, we show that urinary copper elevation is a specific regulatory process mediated by distinct molecules. PET-CT and atomic absorption spectroscopy directly demonstrate an age-dependent decrease in the capacity of Atp7b(-/-) livers to accumulate copper, concomitant with an increase in urinary copper. This reciprocal relationship is specific for copper, indicating that cell necrosis is not the primary cause for the initial phase of metal elevation in the urine. Instead, the urinary copper increase is associated with the down-regulation of the copper-transporter Ctr1 in the liver and appearance of a 2 kDa Small Copper Carrier, SCC, in the urine. SCC is also elevated in the urine of the liver-specific Ctr1(-/-) knockouts, which have normal ATP7B function, suggesting that SCC is a normal metabolite carrying copper in the serum. In agreement with this hypothesis, partially purified SCC-Cu competes with free copper for uptake by Ctr1. Thus, hepatic down-regulation of Ctr1 allows switching to an SCC-mediated removal of copper via kidney when liver function is impaired. These results demonstrate that the body regulates copper export through more than one mechanism; better understanding of urinary copper excretion may contribute to an improved diagnosis and monitoring of WD.
Subject(s)
Copper/urine , Hepatolenticular Degeneration/urine , Liver/metabolism , Adenosine Triphosphatases/deficiency , Adenosine Triphosphatases/genetics , Adenosine Triphosphatases/metabolism , Animals , Bile/metabolism , Cation Transport Proteins/deficiency , Cation Transport Proteins/genetics , Cation Transport Proteins/metabolism , Copper/metabolism , Copper Transporter 1 , Copper-Transporting ATPases , Disease Models, Animal , Down-Regulation , HEK293 Cells , Hepatolenticular Degeneration/genetics , Hepatolenticular Degeneration/metabolism , Hepatolenticular Degeneration/physiopathology , Homeostasis , Humans , Kidney/metabolism , Kidney/physiopathology , Liver/physiopathology , Longitudinal Studies , Mice , Mice, Knockout , Up-RegulationABSTRACT
Wilson disease is an inherited autosomal recessive disorder causing copper accumulation and consequent toxicity. D-Penicillamine, a potent metal chelator, is an important therapy for Wilson disease. To investigate the changes of metal elements under the treatment of D-penicillamine, we determined the levels of Cu, Zn, Mg, Ca, Fe, Se, Mn, Pb, Hg, Cd, As, Tl, and Al by ICP-MS in 24-h urine of 115 Wilson disease patients who had received treatment with D: -penicillamine for 1 month to 22 years at maintenance doses, as well as 115 age-matched, healthy controls. The levels of Cu, Mg, Ca, Zn, Hg, Pb, Tl, Cd, and Mn in the 24-h urine of the cases were significantly higher than those of the controls (P < 0.05), and the observed increases in the levels of Mg, Ca, and Zn were directly correlated with the treatment duration with Pearson Correlation Coefficient (R) of 0.356 (Mg), 0.329 (Ca), and 0.313 (Zn), respectively (P < 0.05). On the other hand, the levels of Al and As in the 24-h urine were lower than those of the controls (P < 0.05) and were negatively correlated with the treatment time with R of -0.337 (Al) and -0.398 (As), respectively, (P < 0.05). Thus, this study indicates that the levels of metal elements may be altered in patients with Wilson disease under the treatment of D-penicillamine.
Subject(s)
Hepatolenticular Degeneration/drug therapy , Hepatolenticular Degeneration/urine , Metals/urine , Penicillamine/therapeutic use , Adolescent , Adult , Chelating Agents/therapeutic use , Child , Child, Preschool , Female , Humans , Male , Middle Aged , Time Factors , Treatment Outcome , Young AdultABSTRACT
BACKGROUND: The relationship between serum 'free' copper and urine copper in patients with Wilson disease has not been explored. AIM: The object of this study is to ascertain if there is a direct relationship between these two parameters. METHOD: The case notes of 320 patients with Wilson disease, seen between 1960 and 1987, have been reviewed. Eighty of these patients had received no treatment before referral and the results of serum 'free' copper and urine copper on admission and at one year of treatment have been analysed. RESULTS: Except for patients with acute haemolysis, the ratio between 'free' serum copper and urine copper before treatment, on average, is around 7:1, after treatment this falls to around 5:1. But results show a wide scatter and there is no direct linear relationship. CONCLUSION: The term 'free' copper is misleading and should be replaced by the more cumbersome but accurate term 'noncaeruloplasmin bound copper'. Most 'free' copper is complexed to albumin and is only available for excretion if there is significant protein loss by the kidneys.
Subject(s)
Copper/blood , Copper/urine , Hepatolenticular Degeneration/blood , Hepatolenticular Degeneration/urine , Adolescent , Adult , Ceruloplasmin/analysis , Chelating Agents/therapeutic use , Child , Child, Preschool , Hepatolenticular Degeneration/drug therapy , Humans , Penicillamine/therapeutic use , Trientine/therapeutic use , Young AdultABSTRACT
BACKGROUND: Urinary copper excretion higher than 100 µg/24 h is useful for diagnosing Wilson's disease. d-Penicillamine challenge test may produce higher levels than 1400 µg/24 h, allowing for better diagnostic accuracy. This study investigated whether heterozygotes reach this value and compared copper serum levels, ceruloplasmin, and urinary copper excretion before and after administering d-penicillamine to the parents of Wilson's disease patients. METHODS: Fifty parents of adult patients were enrolled to obtain copper serum levels and ceruloplasmin along with 24-h urinary copper excretion before and after administering 1g d-penicillamine. RESULTS: Serum ceruloplasmin and copper levels were significantly lower in fathers than in mothers (mean 21.8×27.8 mg%; 71.4×88.0 µg%; p ≤ 0.001). The mean of basal 24-h urinary copper excretion was higher in fathers (26.2×18.7 µg/24 h, p=0.01), but did not differ between the genders after d-penicillamine (521.7×525.3, range 31.6-1085.1 µg/24h, p=0.8). CONCLUSIONS: The mean values of serum copper, ceruloplasmin, and basal urinary copper excretion were different between males and females. The current diagnostic threshold of 24-h urinary copper excretion after d-penicillamine was not reached by heterozygotes. The increased urinary copper excretion after d-penicillamine challenge was much higher than fivefold the upper limit of normal urinary copper excretion in the majority of heterozygotes and should not be taken into account when diagnosing Wilson's disease.
Subject(s)
Copper/urine , Hepatolenticular Degeneration/genetics , Hepatolenticular Degeneration/urine , Ceruloplasmin/metabolism , Chelating Agents , Copper/blood , Female , Hepatolenticular Degeneration/diagnosis , Heterozygote , Humans , Male , Middle Aged , Penicillamine , Sex FactorsABSTRACT
BACKGROUND: It is generally accepted that patients with Wilson's disease excrete excess copper in urine. However, there has been no study, on a large series of patients, as to whether there are differences in the rate of excretion at different stages of the disease or what changes may be expected after treatment. DESIGN: The present study follows from an analysis of the results of urinary copper excretion of 192 patients with Wilson's disease seen between 1955 and 2000. These patients were divided into three groups, pre-symptomatic, hepatic and neurological Wilson's disease. Patients were studied for basal pre-treatment, 24-h urinary copper excretion and for 6 h after a test dose of 500 mg penicillamine. The tests were repeated after approximately 1 and 2 years of chelation therapy with either penicillamine, or in a small minority of cases, trientine. RESULTS: The basal, pre-treatment copper excretion was the lowest in pre-symptomatic patients (207.93 µg/24 h) and the highest in the hepatic patients (465.75 µg/24 h). Those with neurological Wilson's disease gave an intermediate figure (305.58 µg/24 h). The response to penicillamine was the highest in the neurological patients and the lowest in the pre-symptomatic group. After 1 and 2 years of treatment all groups showed significant falls in both the basal and the after penicillamine rate of excretion of copper. The small subgroup treated with trientine, rather than penicillamine, showed similar results. CONCLUSIONS: The rate of copper excretion in patients with Wilson's disease shows wide variation from patient to patient, but in general patients with pre-symptomatic disease excrete less copper than those with symptomatic disease. All groups show a great increase when challenged with penicillamine. After 1 and 2 years of treatment, there is significant decrease in copper excretion in both basal and after penicillamine challenge. This presumably indicates a reduction in the body load of copper.